ストックスクリーナーアプリを入手
2.80
3.70%
0.10
プレマーケット:
2.84
0.04
+1.43%
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech (MBRX) Sees Modest Uptick as Stock Consolidates Near SupportVWAP Bounce - newsline.com
Nano-cap Moleculin Biotech approaches key leukemia trial data unblinding - MSN
Moleculin Biotech Announces Positive Market Assessment for Annamycin in Relapsed/Refractory AML (R/R AML) – Key Clinical Advantages and Unmet Needs Highlighted - Minichart
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy - TipRanks
Moleculin Biotech Reports Strong Physician Interest in Annamycin for R/R AML Treatment, Highlighting Unmet Needs and Positive Market Assessment - Quiver Quantitative
Moleculin market study shows strong physician, payer interest in Annamycin for R/R AML - TradingView
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML - The Manila Times
Strong physician interest in Annamycin reported by Moleculin (NASDAQ: MBRX) - Stock Titan
Leukemia drug Annamycin wins doctor and insurer support in new survey - Stock Titan
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor What This Means Segment - marketscreener.com
Moleculin Biotech (MBRX) Holds Steady at $2.46 – Key Levels in FocusOvervalued Signals - newsline.com
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor 'What This Means” Segment - The Manila Times
Leukemia trial of Annamycin hits 45-patient milestone, mid‑2026 data ahead - Stock Titan
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment - Yahoo Finance
Moleculin Biotech (MBRX) Holds Near Key Support as Modest Uptick Signals Cautious TradingTrend Following Picks - The Legal Advocate
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO - TipRanks
Moleculin Presents ASCO Data Showing No Detectable Cardiotoxicity with Annamycin at High Exposure - TradingView
Moleculin Biotech (MBRX) shares ASCO data on Annamycin cardiac safety and MIRACLE trial - Stock Titan
Moleculin Presents ASCO 2026 Data Demonstrating No - GlobeNewswire
Moleculin Biotech (MBRX) Edges Higher on Modest Volume: Support Holds Near $2.65Early Entry Signals - newsline.com
Moleculin Biotech (MBRX) Holds Steady at $2.73 Amid Consolidation PhaseHigh Reward Trades - newsline.com
Moleculin Biotech (MBRX) Rises 3.27%: Breaking Above Support with Resistance in SightPCR Spike - thelegaladvocate.com
Moleculin Biotech’s MIRACLE Trial Data Exceeds Historical Benchmarks for AML Treatment - geneonline.com
Moleculin Biotech Releases Updated Investor Information Presentation - TipRanks
Moleculin Biotech, Inc. Files SEC Form 8-K and Releases May 2026 Investor Presentation - Minichart
Moleculin Biotech (NASDAQ: MBRX) posts new May 2026 investor presentation - Stock Titan
Moleculin Biotech | 8-K: Current report - Moomoo
Moleculin Biotech (MBRX) Holds Steady at $2.39 as Trading Remains FlatVOLD Alert - newsline.com
Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN
Why Did MBRX Stock Plummet Over 25% Today? - MSN
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan
Moleculin presents cardiac safety data for Annamycin at ASCO By Investing.com - Investing.com South Africa
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin - The Manila Times
Moleculin's Annamycin shows no heart toxicity in trials, advancing AML cancer treatment. - Pluang
Moleculin presents cardiac safety data for Annamycin at ASCO - Investing.com
Moleculin Biotech, Inc. Presents Cardiac Safety Data for Annamycin at 2026 ASCO Annual Meeting - Quiver Quantitative
Pooled trials of cancer drug Annamycin find no cardiotoxicity signal - Stock Titan
Why did MBRX stock climb 14% today? - MSN
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech stock (US60855L2034): Maxim Group keeps Buy rating - AD HOC NEWS
Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX - Moomoo
Moleculin Biotech: Runway to Support Planned Operations Into 3Q 2026 >MBRX - Moomoo
What Does GF Score 27/100 Say About Moleculin Biotech (MBRX) Aft - GuruFocus
Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Q1 2026 Financial Results and Clinical Trial Updates - Minichart
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech Q1 net loss widens as R&D costs rise - TradingView
Moleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission Rate - Quiver Quantitative
MBRX: Pivotal AML trial hits key enrollment, 40% remission rate; Q1 net loss $12.8M, cash runway into Q3 - TradingView
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Moleculin (NASDAQ: MBRX) Q1 2026 loss deepens while MIRACLE AML trial progresses - Stock Titan
Leukemia trial shows 40% remissions; first MIRACLE data unblinding due June 2026 - Stock Titan
Moleculin Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MBRX: Annamycin advanced in pivotal AML trial; net loss widened, and more funding is needed for operations - TradingView
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moleculin Biotech (MBRX) widens Q1 loss and flags funding gap for MIRACLE trial - Stock Titan
Moleculin Biotech (MBRX) Q4 2025 Earnings: $13.04 EPS Surges Past $-6.24 EstimatesForward EPS Estimate - newsline.com
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):